NL8104818A - Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat. - Google Patents
Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat. Download PDFInfo
- Publication number
- NL8104818A NL8104818A NL8104818A NL8104818A NL8104818A NL 8104818 A NL8104818 A NL 8104818A NL 8104818 A NL8104818 A NL 8104818A NL 8104818 A NL8104818 A NL 8104818A NL 8104818 A NL8104818 A NL 8104818A
- Authority
- NL
- Netherlands
- Prior art keywords
- biotin
- insulin
- patient
- serum
- glucose
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 9
- 201000010099 disease Diseases 0.000 title description 8
- 238000002360 preparation method Methods 0.000 title description 3
- 229940126601 medicinal product Drugs 0.000 title description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 323
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 170
- 239000011616 biotin Substances 0.000 claims description 157
- 229960002685 biotin Drugs 0.000 claims description 157
- 235000020958 biotin Nutrition 0.000 claims description 151
- 102000004877 Insulin Human genes 0.000 claims description 85
- 108090001061 Insulin Proteins 0.000 claims description 85
- 229940125396 insulin Drugs 0.000 claims description 85
- 210000002966 serum Anatomy 0.000 claims description 55
- 206010012601 diabetes mellitus Diseases 0.000 claims description 47
- 229940068840 d-biotin Drugs 0.000 claims description 18
- 230000001419 dependent effect Effects 0.000 claims description 16
- 230000037396 body weight Effects 0.000 claims description 15
- 206010018473 Glycosuria Diseases 0.000 claims description 13
- 201000001421 hyperglycemia Diseases 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- 238000007446 glucose tolerance test Methods 0.000 claims description 5
- 230000035780 glucosuria Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 72
- 239000008103 glucose Substances 0.000 description 72
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 39
- 238000002560 therapeutic procedure Methods 0.000 description 25
- 239000000902 placebo Substances 0.000 description 19
- 229940068196 placebo Drugs 0.000 description 19
- 210000002700 urine Anatomy 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 230000007423 decrease Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000012417 linear regression Methods 0.000 description 8
- 230000002485 urinary effect Effects 0.000 description 6
- 239000002131 composite material Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 239000002933 immunoreactive insulin Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000006362 insulin response pathway Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000021411 American diet Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229940079172 Osmotic diuretic Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000009430 Thespesia populnea Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 235000019679 nutrient-rich food Nutrition 0.000 description 1
- 239000002337 osmotic diuretic agent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 235000021194 placebo diet Nutrition 0.000 description 1
- 230000033882 response to biotin Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20078480A | 1980-10-27 | 1980-10-27 | |
| US20078480 | 1980-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8104818A true NL8104818A (nl) | 1982-05-17 |
Family
ID=22743169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8104818A NL8104818A (nl) | 1980-10-27 | 1981-10-26 | Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat. |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5799520A (enExample) |
| AU (1) | AU7683381A (enExample) |
| BE (1) | BE890888A (enExample) |
| DE (1) | DE3142590A1 (enExample) |
| FR (1) | FR2492662A1 (enExample) |
| NL (1) | NL8104818A (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3363567D1 (en) * | 1982-03-01 | 1986-06-26 | Efamol Ltd | Pharmaceutical and dietary composition |
| AU2003266287A1 (en) * | 2002-08-23 | 2004-03-11 | Dsm Ip Assets B.V. | Novel nutraceutical compositions comprising biotin |
| JP2004203863A (ja) * | 2002-12-09 | 2004-07-22 | Taisho Pharmaceut Co Ltd | 抗糖尿病用組成物 |
| JP2006089392A (ja) * | 2004-09-22 | 2006-04-06 | Tohoku Univ | 生活習慣病改善食品および生活習慣病治療薬 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788779A (fr) * | 1971-09-13 | 1973-01-02 | Magnor Inc | Produit a base de biotine pour le traitement du diabete |
-
1981
- 1981-10-26 NL NL8104818A patent/NL8104818A/nl not_active Application Discontinuation
- 1981-10-26 AU AU76833/81A patent/AU7683381A/en not_active Abandoned
- 1981-10-27 FR FR8120147A patent/FR2492662A1/fr active Granted
- 1981-10-27 DE DE19813142590 patent/DE3142590A1/de not_active Withdrawn
- 1981-10-27 BE BE0/206366A patent/BE890888A/fr not_active IP Right Cessation
- 1981-10-27 JP JP56171944A patent/JPS5799520A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU7683381A (en) | 1982-05-06 |
| JPS5799520A (en) | 1982-06-21 |
| DE3142590A1 (de) | 1982-08-12 |
| FR2492662A1 (fr) | 1982-04-30 |
| BE890888A (fr) | 1982-02-15 |
| FR2492662B1 (enExample) | 1985-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bo et al. | A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial | |
| JP5545424B2 (ja) | 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物 | |
| Du et al. | Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options | |
| Proietto | Obesity and weight management at menopause | |
| Laederach‐Hofmann et al. | Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: A randomized, placebo‐controlled double‐blind study | |
| DE69624580T2 (de) | Verfahren und zusammensetzung zur verbesserten parenteralen ernährung | |
| CN101626696B (zh) | 包含糖寡聚物的营养产品 | |
| Hlais et al. | Effect of lysine, vitamin B6, and carnitine supplementation on the lipid profile of male patients with hypertriglyceridemia: a 12-week, open-label, randomized, placebo-controlled trial | |
| EP2397039A1 (en) | Compositions for delaying progression of diabetes using Salacia oblonga extract | |
| EP1397148B1 (en) | Chromium/biotin treatment of dyslipidemia | |
| WO2000045651A1 (en) | Oral arginine and insulin secretion | |
| Matyjaszek-Matuszek et al. | Pharmacotherapy of obesity—state of the art | |
| Landgraf et al. | Therapy of type 2 diabetes | |
| Aberle et al. | Obesity and diabetes | |
| Landgraf et al. | Therapy of Type 2 Diabetes | |
| Alatrach et al. | Dapagliflozin impairs the suppression of endogenous glucose production in type 2 diabetes following oral glucose | |
| Gater et al. | Effects of arginine/lysine supplementation and resistance training on glucose tolerance | |
| NL8104818A (nl) | Geneesmiddel voor het behandelen van suikerziekte en werkwijze voor de toediening van het preparaat. | |
| Palana et al. | Analyzing the effects of semaglutide (Ozempic/Wegovy) on metabolism: Investigating correlations with weight reduction | |
| KR20220157906A (ko) | 이나보글리플로진을 포함하는 개과 동물의 당뇨병 예방 또는 치료용 약학 조성물 | |
| CN101610790B (zh) | 新颖的组合物及其用途 | |
| Sugiyama et al. | Type 2 diabetes remission and substantial body weight reduction achieved with metformin and a sodium-glucose cotransporter 2 inhibitor | |
| AU2015329581B2 (en) | Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia | |
| US5846544A (en) | Composition and method for reducing blood sugar levels in diabetic humans | |
| US20100028457A1 (en) | Agent for prevention or treatment of blood glucose level elevation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |